Clinical Trial

Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)

Study acronym: IMPHROVE-D
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with liver cirrhosis. It has been demonstrated that antiviral therapy in patients with chronic hepatitis C infection leads to a decrease of PH and is associated with an improved outcome. Recently, Bulevirtide was approved for the treatment of patients coinfected with hepatitis B (HBV) and chronic hepatitis delta (HDV) infection, which helps to achieve viral supression in these patients. This study investigates the potential effects of viral supression on PH in patients with chronic HBV/HDV infection and liver cirrhosis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-04-26; most recent amendment 2025-09-08.
Status change: Recruiting → Active, Not Recruiting 2025-09-08
Trial Details
NCT Number NCT04863703
Lead Sponsor Hannover Medical School
Conditions Hepatitis D, Hepatitis B, Portal Hypertension, Liver Cirrhosis
Enrollment 11 participants
Start Date 2021-05-07
Primary Completion 2024-11-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-15